替雷利珠单抗致自身免疫性多内分泌腺病综合征1例  

Autoimmune polyendocrine syndrome caused by tislelizumab:one case report

作　　者：汪龙[1] 张莉 朱玲娜[1] 程军[1] 徐涵 WANG Long;ZHANG Li;ZHU Lingna;CHENG Jun;XU Han(Department of Pharmacy,Third People’s Hospital of Bengbu,Anhui Bengbu 233099,China;Department of Pharmacy,Second Affiliated Hospi-tal,Bengbu Medical University,Anhui Bengbu 233004,China;Department of Medical Oncology,Third People’s Hospital of Bengbu,Anhui Bengbu 233099,China)

机构地区：[1]蚌埠市第三人民医院药学部,安徽蚌埠233099 [2]蚌埠医科大学第二附属医院药学部,安徽蚌埠233004 [3]蚌埠市第三人民医院肿瘤内科,安徽蚌埠233099

出　　处：《中国医院药学杂志》2024年第20期2429-2432,共4页Chinese Journal of Hospital Pharmacy

基　　金：蚌埠医学院自然科学重点项目(编号:2022byzd097)。

摘　　要：替雷利珠单抗是一种靶向程序性死亡受体-1的IgG4单克隆抗体,主要用于治疗非小细胞肺癌、尿路上皮癌等。本文报道1例晚期肺癌患者在应用替雷利珠单抗后,发生以“1型糖尿病并发酮症酸中毒”及“甲状腺功能减退”为主要表现的自身免疫性多内分泌腺病综合征,以期提高医务人员对此药所致罕见不良事件的认识。As an anti-programmed death 1(PD-1)mono-clonal immunoglobulin G4 antibody,tislelizumab is com-monly applied for treating non-small cell lung cancer and uro-thelial carcinoma.In a female patient of advanced lung cancer on tirellizumab,autoimmune polyendocrine syndrome was accompanied by type 1 diabetes mellitus complicated with ketoacidosis and hypothyroidism.It helped to enhance clini-cians’understanding of rare adverse events caused by tislelizumab.

关 键 词：替雷利珠单抗 免疫检查点抑制剂 不良事件 自身免疫性多内分泌腺病综合征 

分 类 号：R979.1[医药卫生—药品]